relapses

Early use of immunosuppressive therapy — when compared with a later treatment start — was associated with fewer relapses and reduced disability among neuromyelitis optica spectrum disorder (NMOSD) patients with self-reactive antibodies against the AQP4 protein, a study from China showed. The data demonstrated a time-dependent treatment efficacy, with…

The composition of bacteria in the gut is altered in neuromyelitis optica spectrum disorder (NMOSD) patients experiencing disease relapses compared with healthy people in the same household, a study reports. Following treatment, however, the gut bacterial profiles of NMOSD patients in remission resembled those of healthy people. “The…

Uplizna (inebilizumab) treatment markedly reduces the number of several subsets of immune B-cells that are linked to disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD), trial data show. The therapy also lowers levels of the self-reactive antibodies against the AQP4 protein that drive most NMOSD cases,…

None of the neuromyelitis optica spectrum disorder (NMOSD) patients in the Phase 3 CHAMPION-NMOSD clinical trial have had a disease relapse while on Ultomiris (ravulizumab-cwvz) treatment for a median of more than 2.5 years. These findings were shared by Sean Pittock, MD, the trial’s principal investigator, at the…

Tocilizumab, an anti-inflammatory medication used off-label for neuromyelitis optica spectrum disorder (NMOSD), can help prevent relapses (flare-ups) and ease disability while being generally safe, according to a meta-analysis. The study, “Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety,” was published in the journal…

Nearly two in 10 neuromyelitis optica spectrum disorder (NMOSD) patients develop new asymptomatic brain and spinal cord lesions during the period of disease remission, but these do not appear to increase risk of relapse, according to a study in Argentina. Asymptomatic, or silent, lesions are those that can be…

The presence of certain self-reactive antibodies called antinuclear antibodies (ANAs) in the blood is associated with worse disability and more severe relapses in people with neuromyelitis optica spectrum disorder (NMOSD), according to a study from China. “Our results suggest that ANA seems to be more associated with severe disease…

People with neuromyelitis optica spectrum disorder (NMOSD) who experience relapses are three times more likely to change their treatment regimen than those who have no relapses, a study found. Researchers also observed that people who experienced optic neuritis with or without brain symptoms, those with shorter disease duration, and…

Summer is one of my favorite times of the year. The days are longer, the adventures seem endless, and the smell of barbecue, flowers, and freshly cut grass fill the air. However, high temperatures during the summer, especially in tropical climates, can pose a challenge for those with neuromyelitis…